tert-butyl 4-allyl-4-(hydroxymethyl)piperidine-1-carboxylate | 236406-37-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-allyl-4-(hydroxymethyl)piperidine-1-carboxylate
• 英文别名: 4-allyl-N-t-butoxycarbonylpiperidine-4-methanol；tert-butyl 4-(hydroxymethyl)-4-(prop-2-en-1-yl)piperidine-1-carboxylate；tert-butyl 4-(hydroxymethyl)-4-prop-2-enylpiperidine-1-carboxylate
• CAS: 236406-37-4
• 化学式: C₁₄H₂₅NO₃
• 分子量: 255.357
• InChiKey: MANSFZGRKKLTRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-allyl-4-(hydroxymethyl)piperidine-1-carboxylate 在 sodium periodate 、 sodium borohydrid 、 碳酸氢钠 、 sodium sulfite 作用下， 以 四氢呋喃 、 甲醇 、 水 、 丙酮 为溶剂， 生成 2,8-二氮杂螺[4.5]癸烷-8-羧酸叔丁酯
  参考文献：
  名称：

  N-acyl cyclic amine derivatives

  摘要：

  该发明涉及由通式[I]表示的化合物 ##STR1## [其中Ar表示芳基或杂环基，可能具有从卤原子、较低烷基基团和较低烷氧基团中选择的取代基; R.sup.1表示可用氟原子取代的C.sub.3-C.sub.6环烷基基团; R.sup.2和R.sup.4表示氢原子，表示为--(A.sup.1).sub.m--NH--B或类似基团; R.sup.3和R.sup.5表示氢原子，可用较低烷基基团取代的C.sub.1-C.sub.6脂肪烃基团或类似基团; n表示0或1; X表示氧原子或硫原子]。根据该发明的化合物，由于它们不仅具有对M.sub.3胆碱能受体具有强效选择性拮抗活性，而且表现出优异的口服活性、持久作用和药代动力学特性，因此在对抗呼吸、泌尿和消化系统疾病时非常有用，且副作用很小，是安全有效的药物。

  公开号：

  US06140333A1
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸甲酯 在 二异丁基氢化铝 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 tert-butyl 4-allyl-4-(hydroxymethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors

  摘要：

  Replacement of the amide functionality in IM491 (N-hydroxy-(5S,6S)-1-methyl-6-{[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl}-5-piperidinecarboxamide) with a sulfonyl group led to a new series of alpha,beta-cyclic and beta,beta-cyclic gamma-sulfonyl hydroxamic acids, which were potent TNF-alpha converting enzyme (TACE) inhibitors. Among them, inhibitor 4b (N-hydroxy(4S,5S)-1-methyl-5-1[4-(2-methyl-4-quinolinylmethoxy)phenyl]sulfonylmethyl -4-pyrrolidinecarboxamide) exhibited IC50 values of <1 nM and 180 nM in porcine TACE (pTACE) and cell assays, respectively, with excellent selectivity over MMP- 1, -2, -9 and - 13 and was orally bioavailable with an F value of 46% in mice. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.06.049

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2123652A1

  公开（公告）日：2009-11-25

  The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein each symbol is as in the specification, or a salt thereof.

  本发明提供了一种具有ACC抑制作用的化合物，该化合物用于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉减少症、癌症等疾病，并具有优异的疗效。 本发明提供了一种由公式（I）表示的化合物： 其中每个符号如说明书所述，或其盐。
• Copper(I)-Catalyzed Borylative <i>exo</i>-Cyclization of Alkenyl Halides Containing Unactivated Double Bond
  作者：Koji Kubota、Eiji Yamamoto、Hajime Ito

  DOI：10.1021/ja3104582

  日期：2013.2.20

  A borylative exo-cyclization of alkenyl halides has been reported. The reaction includes the regioselective addition of a borylcopper(I) intermediate to unactivated terminal alkenes, followed by the intramolecular substitution of the resulting alkylcopper(I) moiety for the halide leaving groups. Experimental and theoretical investigations of the reaction mechanism have also been described. This reaction

  已经报道了烯基卤化物的硼酸化外环化。该反应包括将硼基铜 (I) 中间体区域选择性加成到未活化的末端烯烃，然后将所得烷基铜 (I) 部分分子内取代为卤化物离去基团。还描述了反应机理的实验和理论研究。该反应为从简单的原料合成含有应变环烷基结构的烷基硼酸酯提供了一种新方法。
• Oxa-spirocycles: synthesis, properties and applications
  作者：Kateryna Fominova、Taras Diachuk、Dmitry Granat、Taras Savchuk、Vladyslav Vilchynskyi、Oleksiy Svitlychnyi、Vladyslav Meliantsev、Igor Kovalchuk、Eduard Litskan、Vadym V. Levterov、Valentyn R. Badlo、Ruslan I. Vaskevych、Alla I. Vaskevych、Andrii V. Bolbut、Volodymyr V. Semeno、Rustam Iminov、Kostiantyn Shvydenko、Anastasiia S. Kuznetsova、Yurii V. Dmytriv、Daniil Vysochyn、Vasyl Ripenko、Andrei A. Tolmachev、Olexandra Pavlova、Halyna Kuznietsova、Iryna Pishel、Petro Borysko、Pavel K. Mykhailiuk

  DOI：10.1039/d1sc03615g

  日期：——

  A general practical approach to a new generation of spirocyclic molecules – oxa-spirocycles – is developed.

  开发了一种新一代螺环分子 - 氧杂螺环 - 的一般实用方法。
• Organophotocatalytic carbo-heterofunctionalization of unactivated olefins with pendant nucleophiles
  作者：David M. Fischer、Manuel Freis、Willi M. Amberg、Henry Lindner、Erick M. Carreira

  DOI：10.1039/d3sc02250a

  日期：——

  The difunctionalization of unactivated, terminal olefins through intermolecular addition of α-bromoketones, -esters, and -nitriles followed by formation of 4- to 6-membered heterocycles with pendant nucleophiles is reported.

  报告介绍了通过 α-溴酮类、-酯类和-硝酸酯类的分子间加成，对未活化的末端烯烃进行双官能化，然后与悬挂的亲核物形成 4 至 6 元杂环的过程。
• N-ACYL CYCLIC AMINE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1061076A1

  公开（公告）日：2000-12-20

  The invention relates to compounds represented by the general formula [I] [wherein Ar means an aryl group or a heteroaryl group which may have a substitutive group selected from a group consisting of a halogen atom, a lower alkyl group and a lower alkoxy group; R1 means a C3-C6 cycloalkyl group which is substitutable with a fluorine atom; R2 and R4 mean hydrogen atoms, groups represented by -(A1)m-NH-B or the like; R3 and R5 mean hydrogen atoms, C1-C6 aliphatic hydrocarbon groups or the like which are substitutable with a lower alkyl group(s) ; n means 0 or 1; and X means an oxygen atom or a sulfur atom]. Compounds according to the invention, since they not only have potent selective antagonistic activity against muscarinic M3 receptors but also exhibit excellent oral activity, durability of action and pharmacokinetics, are very useful as safe and effective remedies against respiratory, urinary and digestive diseases with little adverse side effects.

  本发明涉及通式[I]所代表的化合物。 [其中 Ar 指芳基或杂芳基，可带有选自卤原子、低级烷基和低级烷氧基的取代基团；R1 指可被氟原子取代的 C3-C6 环烷基；R2和R4指氢原子、由-(A1)m-NH-B代表的基团或类似基团；R3和R5指氢原子、可被低级烷基取代的C1-C6脂族烃基或类似基团；n指0或1；X指氧原子或硫原子]。 根据本发明的化合物不仅对毒蕈碱类 M3 受体具有强效的选择性拮抗活性，而且具有良好的口服活性、作用持久性和药代动力学，因此非常适合作为安全有效的治疗呼吸系统、泌尿系统和消化系统疾病的药物，且不良副作用小。